Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, et al. A learning program for treatment recommendations by molecular tumor boards and artificial intelligence. JAMA Oncology. 2024. 10. 95-102
Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, et al. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2022. 33. 2. 216-226
Hidetoshi Hayashi, Yuichi Takiguchi, Hironobu Minami, Kohei Akiyoshi, Yoshihiko Segawa, Hiroki Ued, Yasuo Iwamoto, Chihiro Kondoh, Koji Matsumoto, Shin Takahashi, et al. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: a Nonrandomized Phase 2 Clinical Trial. JAMA Oncology. 2020. 6. 12. 1-9
Sunakawa Y, Mogushi K, Lenz H, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, et al. Tumor sideness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer. Molecular Cancer Therapeutics. 2018. 17. 12. 2788-2795
Updated analysis from a phase II study on the efficacy of Nivolumab in patients with cancer of unknown primary (NivoCUP)
(第20回日本臨床腫瘍学会学術集会 2023)
Phase II Trial of Site-Specific Treatment Based on Gene Expression and Mutation Profiling by NGS for Patients with Cancer of Unknown Primary (CUP)
(第18回日本臨床腫瘍学会学術集会 2021)
A phase II study on the efficacy of Nivolumab in patients with cancer of unknown primary (CUP) (NivoCUP)
(第18回日本臨床腫瘍学会学術集会 2021)
NivoCUP: An open label phase 2 study on the efficacy of Nivolumab in cancer of unknown primary (CUP)
(Annual Meeting of ASCO 2020 2020)
日本臨床腫瘍学会
, American Society of Clinical Oncology
, 日本内科学会
, 日本呼吸器学会
, International Association for the Study of Lung Cancer
, 日本肺癌学会
, 日本癌学会
, 日本癌治療学会
, 日本呼吸器内視鏡学会